<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1560-4381</journal-id>
<journal-title><![CDATA[Correo Científico Médico]]></journal-title>
<abbrev-journal-title><![CDATA[ccm]]></abbrev-journal-title>
<issn>1560-4381</issn>
<publisher>
<publisher-name><![CDATA[Universidad Ciencias Médicas de Holguín]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1560-43812019000300764</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Parámetros de laboratorio para el cáncer de cabeza y cuello tratado con Nimotuzumab]]></article-title>
<article-title xml:lang="en"><![CDATA[Laboratory parameters for head and neck cancer treated with Nimotuzumab]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Batista]]></surname>
<given-names><![CDATA[Yuniet]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Berlanga]]></surname>
<given-names><![CDATA[Ana María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Pifferrer]]></surname>
<given-names><![CDATA[Gretel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez Torres]]></surname>
<given-names><![CDATA[Dayalí Teresa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Docente Vladimir Ilich Lenin  ]]></institution>
<addr-line><![CDATA[Holguín ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario Clínico Quirúrgico Lucía Íñiguez Landín  ]]></institution>
<addr-line><![CDATA[Holguín ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2019</year>
</pub-date>
<volume>23</volume>
<numero>3</numero>
<fpage>764</fpage>
<lpage>781</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1560-43812019000300764&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1560-43812019000300764&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1560-43812019000300764&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  el Nimotuzumab es un anticuerpo monoclonal utilizado en el tratamiento del cáncer de cabeza y cuello.  Objetivo:  valorar el comportamiento de los resultados de los exámenes de laboratorio en los pacientes con cáncer de cabeza y cuello en estadios avanzados que participaron en el ensayo clínico fase IV con Nimotuzumab.  Métodos:  estudio de serie de casos, en una muestra de 30 pacientes con cáncer de cabeza y cuello en estadios avanzados, que participaron en el ensayo clínico fase IV con Nimotuzumab, en el periodo comprendido desde febrero de 2012 a febrero de 2015 en el Hospital General Docente Vladimir Ilich Lenin, Holguín, Cuba, en las consultas de otorrinolaringología-oncológicas y el Departamento de Ensayos clínicos, con el empleo de determinaciones cuantitativas de los parámetros investigados. Se utilizaron medidas descriptivas y de asociación.  Resultados:  existió un predominio en pacientes masculinos mayores de 60 años, fumadores y alcohólicos. Las reacciones adversas que más se presentaron fueron las hematológicas, como la anemia (33%). Los valores medios de la fosfatasa alcalina y deshidrogenasa láctica en los cuatro esquemas de tratamiento y durante todas las etapas, se mantuvieron dentro de límites normales, excepto en el esquema B, que a los 2 años el promedio de la LDH, estuvo sobre los valores de referencia.  Conclusiones:  la anemia constituyó la reacción adversa más frecuente en todos los esquemas de tratamiento; la fosfatasa alcalina y la deshidrogenasa láctica no mostraron variaciones evolutivas relevantes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Nimotuzumab is a humanized monoclonal antibody used in the treatment of head and neck cancer.  Objective:  to assess lab exams results in patients with advanced head and neck cancer, who participated in the Phase-IV clinical trial with Nimotuzumab.  Methods: a series of cases study, in a sample of 30 patients with advanced head and neck cancer, who participated in the Phase-IV clinical trial with Nimotuzumab, from February 2012 to February 2015, at Vladimir Ilich Lenin General Hospital at Oncological Otorhinolaryngology consultation and the Clinical Trials Department, using quantitative determinations for previous researched parameters. Descriptive and associating measures were used.  Results:  there was a predominant trend in patients over 60 years old, smokers and alcoholics. The most common adverse reactions were hematologic, out of them anemia reached 33 %. The average values of alkaline phosphatase (ALPs) and lactate dehydrogenase (LD) in the four treatment schemes and during all stages, were kept within normal limits, except in Scheme B, in which after two years, the average LDH value was higher than referenced values.   Conclusions:  Anemia turned to be the most frequent adverse reaction in all treatment schemes, alkaline phosphatase and lactate dehydrogenase did no show relevant evolutional variations.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Nimotuzumab]]></kwd>
<kwd lng="es"><![CDATA[terapia biológica del cáncer]]></kwd>
<kwd lng="es"><![CDATA[receptor del factor de crecimiento epidérmico]]></kwd>
<kwd lng="en"><![CDATA[Nimotuzumab]]></kwd>
<kwd lng="en"><![CDATA[biological therapy of cancer]]></kwd>
<kwd lng="en"><![CDATA[receptor of epidermis-growth factor]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kasper]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Fauci]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hauser]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Longo]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Jameson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Isselbacher]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de cabeza y cuello]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Harrison]]></surname>
</name>
</person-group>
<source><![CDATA[Principios de Medicina Interna]]></source>
<year>2006</year>
<edition>16</edition>
<page-range>2996-3011</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Harrison`s]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Cuba. Ministerio de Salud Pública</collab>
<source><![CDATA[Anuario estadístico de Cuba]]></source>
<year>2014</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardemil]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología del carcinoma escamoso de cabeza y cuello]]></article-title>
<source><![CDATA[Rev Chilena Cir]]></source>
<year>2014</year>
<volume>66</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>614-20</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farrera]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tolívar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Colella]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Vilaplana]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Grau de Castro]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de cabeza y cuello]]></article-title>
<collab>Farrera</collab>
<source><![CDATA[Medicina Interna]]></source>
<year>2000</year>
<edition>14</edition>
<page-range>p2682-93</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Harcourt S.A]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bologna]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Virus del papiloma humano y el cáncer de cabeza y cuello: revisión de la literatura desde México y Colombia]]></article-title>
<source><![CDATA[Univ Odontol]]></source>
<year>2012</year>
<volume>31</volume>
<numero>67</numero>
<issue>67</issue>
<page-range>149-57</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lever Rosas]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Silva Ortiz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Montes]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Maldonado Magos]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez Parra]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Zincer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sarcoma de parótida. Reporte de un caso y revisión de la literatura]]></article-title>
<source><![CDATA[Rev Sanid Milit Mex]]></source>
<year>2014</year>
<volume>68</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>189-95</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suárez García]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Martínez]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Rojas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Pupo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización de adultos mayores con cáncer de cabeza y cuello]]></article-title>
<source><![CDATA[CCM]]></source>
<year>2013</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mauriz]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Ordoñez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Priego Domínguez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[González Gallego]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La Biotecnología en la salud humana: El hito de los anticuerpos monoclonales]]></article-title>
<source><![CDATA[Ambiociencias]]></source>
<year>2014</year>
<volume>12</volume>
<page-range>12-33</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bermúdez Carvajal]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hidalgo Carrillo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mora Mata]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Mora]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ysmael-Acle Sánchez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mora Román]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticuerpos monoclonales biespecíficos: desarrollo, producción y uso como terapia a anticancerígena]]></article-title>
<source><![CDATA[Rev Méd Univ Costa Rica]]></source>
<year>2019</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fuenmayor]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gamez Hoyos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Montaño]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticuerpos monoclonales en el tratamiento del cáncer. Terapia dirigida para tumores sólidos]]></article-title>
<source><![CDATA[Rev Venezolana Oncol]]></source>
<year>2013</year>
<volume>25</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>236-54</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Merino]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticuerpos monoclonales. Aspectos básicos]]></article-title>
<source><![CDATA[Neurología]]></source>
<year>2011</year>
<volume>26</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>301-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De León]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pareja]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunología del cáncer II: bases moleculares y celulares de la carcinogénesis]]></article-title>
<source><![CDATA[Horiz Med]]></source>
<year>2019</year>
<volume>19</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>84-92</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Escobar Álvarez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Khosravi Shahi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Encinas García]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Izarzugaza Perón]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad de Cetuximab en monoterapia en el tratamiento de cánceres de cabeza y cuello avanzado refractario]]></article-title>
<source><![CDATA[An Med Interna (Madrid)]]></source>
<year>2008</year>
<volume>25</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>159-62</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saurez Martínez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bencomo Yanes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nimotuzumab, effective immunotherapy for the treatment of malignant epithelial tumors]]></article-title>
<source><![CDATA[Biotecnol Apl]]></source>
<year>2014</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>150-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartimath]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[El-Sayed]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Makhlouf]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bernhard]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft]]></article-title>
<source><![CDATA[Oncotarget]]></source>
<year>2019</year>
<volume>10</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1031-44</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial]]></article-title>
<source><![CDATA[Cancer Sci]]></source>
<year>2016</year>
<volume>107</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>486-90</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<collab>Cuba. Ministerio de Salud Pública</collab>
<source><![CDATA[CIMAher® (Nimotuzumab). Resumen de las Características del Producto]]></source>
<year></year>
<publisher-name><![CDATA[CECMED]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acosta Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Valdés]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Viada González]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos Suzarte]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Corrales Reyna]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Frías Blanco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mejoras en el acceso a la información de los ensayos clínicos]]></article-title>
<source><![CDATA[Rev Cubana Sal Púb]]></source>
<year>2010</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>285-8</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez Ruiz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pascau Illas]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Estévez Iglesias]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno Bermúdez]]></surname>
<given-names><![CDATA[YG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Manejo y control de los productos y medicamentos empleados en ensayos clínicos]]></article-title>
<source><![CDATA[Rev Cubana Farm]]></source>
<year>2011</year>
<volume>45</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez Machín]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yeras García]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Registro de ensayos clínicos: un requisito obligatorio para considerar su publicación en revistas científicas]]></article-title>
<source><![CDATA[ACIMED]]></source>
<year></year>
<volume>17</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez Escribano]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ceballos Viro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Filipovich Vegas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Alés Martínez]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Martín Hernández]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Terapia individualizada en carcinoma epidermoide de cabeza y cuello localmente avanzado]]></article-title>
<source><![CDATA[Rev Soc Otorrinolaringol Castilla Leon Cantab La Rioja]]></source>
<year>2013</year>
<volume>4</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>165-74</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar Saini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Srivastava]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar Dixit]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gefitinib concurrente con quimio radiación en el cáncer de cabeza y cuello localmente avanzado]]></article-title>
<source><![CDATA[Gac Mexicana Oncol]]></source>
<year>2016</year>
<volume>15</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>138-44</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carreras]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Monterde]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuevas estrategias terapéuticas en el tratamiento del cáncer]]></article-title>
<source><![CDATA[Servicio de Farmacia Hospital Universitario Vald&#8217;Hebron]]></source>
<year>2014</year>
<page-range>1-20</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Siu]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Abdul Razak]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early phase clinical trials to identify optimal dosing and safety]]></article-title>
<source><![CDATA[Mol Oncol]]></source>
<year>2015</year>
<volume>9</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>997-1007</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Atariguana]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Karlsruher]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Giannini]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento no quirúrgico en cáncer epidermoide de orofarínge avanzado. Análisis de resultados oncológicos en función del subsitio tumoral y fraccionamiento de radioterapia]]></article-title>
<source><![CDATA[Rev Chilena Cir]]></source>
<year>2016</year>
<volume>68</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>355-62</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harari]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiation combined with EGFR signal inhibitors: Head and neck cancer focus]]></article-title>
<source><![CDATA[Semin Radiat Oncol]]></source>
<year>2006</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38-44</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clavo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Zapatero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[de la Torre]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Porto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radioterapia y anemia: nuevas bases]]></article-title>
<source><![CDATA[Oncología]]></source>
<year>2004</year>
<volume>27</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>384-7</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García González]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Heredia Gutiérrez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Neri Torres]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera Cruz]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Dávila Serapio]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilidad de la biometría hemática en la práctica clínica]]></article-title>
<source><![CDATA[Rev Sanid Milit Mexico]]></source>
<year>2012</year>
<volume>66</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38-46</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barba Evia]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Laboratorio clínico y oncología: De los aspectos básicos del cáncer a los tumores más frecuentes y la utilidad de los marcadores tumorales como métodos diagnósticos]]></article-title>
<source><![CDATA[Rev Latinoam Patol Clin Med Lab]]></source>
<year>2013</year>
<volume>60</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>166-96</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barba Evia]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Laboratorio clínico y oncología: De los aspectos básicos del cáncer a los tumores más frecuentes y la utilidad de los marcadores tumorales como métodos diagnosticos]]></article-title>
<source><![CDATA[Rev Latinoam Patol Clin Med Lab]]></source>
<year>2013</year>
<volume>60</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>166-96</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peng]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Shilpa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wilbur]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bowne]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Pincus]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Pherson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<collab>Henry&#8217;s Clinical Diagnosis and Management by Laboratory Methods</collab>
<source><![CDATA[Diagnosis and management of cancer using serologic and tissue tumor markers]]></source>
<year>2011</year>
<edition>22</edition>
<publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Block R]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schimnich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Body fluid analysis: Clinical utility and applicability of published studies to guide interpretation of today&#8217;s laboratory testing in serous fluids]]></article-title>
<source><![CDATA[Crit Rev Clin Lab Sci]]></source>
<year>2013</year>
<volume>50</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>107-24</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shetty]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Chadha]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Babu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kumari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bhat]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Achalli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Salivary lactate dehydrogenase levels in oral leukoplakia and oral squamous cell carcinoma: A biochemical and clinic pathological study]]></article-title>
<source><![CDATA[J Cancer Res Ther]]></source>
<year>2012</year>
<volume>8</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>123-5</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pereda Meira]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[García Figueredo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez Ayerbe]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El precursor del factor de crecimiento epidérmico. Perspectivas de su utilización como marcador tumoral]]></article-title>
<source><![CDATA[Rev Cubana Med]]></source>
<year>2004</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-41</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
